Sandra M. Cardoso
Coimbra, 3004504, Portugal
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
Emerging Roles of Rivastigmine Derivatives Bearing Antioxidant Motifs as Multi-Target Agents for the Management of Neurodegenerative Diseases.
Journal: International journal of molecular sciences
Published: March 16, 2026
Rivastigmine Templates with Antioxidant Motifs-A Medicinal Chemist's Toolbox Towards New Multipotent AD Drugs.
Journal: Antioxidants (Basel, Switzerland)
Published: May 14, 2025
Eco-friendly development of sterile chitosan-based aerogels for wound dressing applications using integrated scCO2 processing.
Journal: International journal of pharmaceutics
Published: May 02, 2025
Impact of Nutrition on the Gut Microbiota: Implications for Parkinson's Disease.
Journal: Nutrition reviews
Published: January 15, 2025
Unveiling Butyrate as a Parkinson's Disease Therapy.
Journal: Neuroscience bulletin
Published: December 07, 2024
Bacterial extracellular vesicles at the interface of gut microbiota and immunity.
Journal: Gut microbes
Published: September 28, 2024
Exploiting the potential of rivastigmine-melatonin derivatives as multitarget metal-modulating drugs for neurodegenerative diseases.
Journal: Journal of inorganic biochemistry
Published: July 01, 2024
The Gut-Brain Axis in Alzheimer's and Parkinson's Diseases: The Catalytic Role of Mitochondria.
Journal: Journal of Alzheimer's disease : JAD
Published: June 14, 2024
Gut-first Parkinson's disease is encoded by gut dysbiome.
Journal: Molecular neurodegeneration
Published: June 13, 2024
Neuronal control of microglia through the mitochondria.
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: February 23, 2024
Nocardia cyriacigeorgica Elicits Gut Disturbances in a Leaky Gut Model of Colitis, but Not the Harmful Cascade Leading to Gut-First Parkinson's Disease.
Journal: International journal of molecular sciences
Published: January 24, 2024
New Multitarget Rivastigmine-Indole Hybrids as Potential Drug Candidates for Alzheimer's Disease.
Journal: Pharmaceutics
Published: January 15, 2024
Last Updated: 09/26/2026